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Human carotid plaque components interact directly with circulating blood elements and thus they might aﬀect each other. We
determined plaque paraoxonase1 (PON1) hydrolytic-catalytic activity and compared plaque and blood levels of lipids, HDL,
PON1, and HbA1c, as well as plaque-oxidized lipids in symptomatic and asymptomatic patients. Human carotid plaques were
obtained from symptomatic and asymptomatic patients undergoing routine endarterectomy, and the lesions were ground and
extracted for PON activity and lipid content determinations. Plaque PONs preserved paraoxonase, arylesterase, and lactonase
activities.ThePON1-speciﬁcinhibitor2-hydroxyquinolinealmostcompletelyinhibitedparaoxonaseandlactonaseactivities,while
only moderately inhibiting arylesterase activity. Oxysterol and triglyceride levels in plaques from symptomatic and asymptomatic
patients did not diﬀer signiﬁcantly, but plaques from symptomatic patients had signiﬁcantly higher (135%) linoleic acid
hydroperoxide (LA-13OOH) levels. Their serum PON1 activity, cholesterol and triglyceride levels did not diﬀer signiﬁcantly, but
symptomatic patients had signiﬁcantly lower (28%) serum HDL levels and higher (18%) HbA1c levels. Thus LA-13OOH, a major
atherogenic plaque element, showed signiﬁcant negative correlations with serum PON1 activity and HDL levels, and a positive
correlation with the prodiabetic atherogenic HbA1c. Plaque PON1 retains its activity and may decrease plaque atherogenicity by
reducingspeciﬁcoxidizedlipids(e.g.,LA-13OOH).TheinversecorrelationbetweenplaqueLA-13OOHlevelandserumHDLlevel
and PON1 activity suggests a role for serum HDL and PON1 in LA-13OOH accumulation.
1.Introduction
The human atherosclerotic plaque is characterized by in-
creased levels of oxidized lipoproteins, such as LDL, HDL,
phospholipids, triglycerides [1, 2], oxidized cholesterol
products (oxysterols) [3], FFAs, and fatty acid derivatives
[4], as well as proteins such as ﬁbrinogen, apolipoprotein
A-I (apoA-I), clusterin, and paraoxonase (PON) [5, 6].
Accumulating cholesterol in the plaque tends to precipitate
and crystallize, forming sharp edges with increased volume
leading to rupture-prone ﬁbrous caps [7]. These “vulnerable
plaques” have several features that diﬀerentiate them from
their nonvulnerable counterparts: vulnerable plaques are less
stable,characterizedbyalargelipidcore,thinﬁbrouscapand
less collagen, intraplaque hemorrhaging and inﬁltration of
inﬂammatory cells without calciﬁcation [8]. These unstable
plaques are associated with increased ischemic events, and
about20%ofischemicstrokesareattributedtocarotidartery
atherosclerosis. Diﬀerentiating asymptomatic from symp-
tomatic patients is important in determining the appropriate
treatment. Major serum biomarkers of plaque vulnerability
are related to inﬂammatory and proteolytic markers, yet2 Journal of Lipids
no biomarkers exist for regular clinical use to indicate high
risk of neurological events and to select patients for carotid
surgery [8].
Mammalian PONs (PON1, PON2, and PON3) are a
unique family of calcium-dependent esterases/lactonases.
ManyoftheantiatherogenicpropertiesofHDLareattributed
to PON1. This enzyme reduces macrophages’ cellular oxida-
tive stress, decreases cholesterol-biosynthesis rate, and stim-
ulates HDL-mediated macrophage cholesterol eﬄux, thus
protecting against foam-cell formation and atherogenesis [9,
10]. PON1-deﬁcient mice are susceptible to the development
of atherosclerosis [11], whereas overexpression of human
PON1 in mice inhibits atherosclerosis development [12].
Epidemiological evidence demonstrates that low PON1
activity is associated with increased risk of cardiovascular
disease [13]. HDL-PON1 antioxidant activity has been
correlated with carotid intima-media thickness [14]. The
hydrolytic lactonase, arylesterase, and paraoxonase activities
of PON1 are all inactivated under oxidative stress [15].
Immunohistochemical analysis has shown accumulation of
PON1 in the human lesion as it progresses from fatty streak
to advanced lesion [5, 16].
PON2 is expressed in most tissues, including macropha-
ges [5]. Like PON1, PON2 has also been shown to protect
vascular cells from oxidative stress, decrease triglyceride
accumulationinmacrophages[10,17,18],playaroleagainst
inﬂammation, and exhibit high acylhomoserine lactone
hydrolysis. PON3, like PON1, is associated with HDL but
does not exhibit paraoxonase activity and is 200 times less
abundant [19].
We recently reported that lipids derived from carotid
atherosclerotic plaque (lesion lipids extract—LLE) can
accelerate macrophage and lipoprotein oxidation and pos-
sess atherogenic properties [20], with the formation of
macrophages with foam cell-like appearance [21]. Incuba-
tion of recombinant PON1 (rePON1) with LLE reduces lipid
carotid plaque atherogenicity [20, 21] but at the same time,
linoleic acid hydroperoxide (LA-13OOH) present in the
LLE inhibits rePON1 paraoxonase and lactonase activities
via reaction of LA-13OOH with the enzyme’s cysteine at
position 284 (Cys284) [22]. These dual eﬀects between
plaque constituents and the elements that are in contact
with them, such as blood components (lipids, proteins)
circulating via the lesion, led us to further investigate (a)
if PONs present in the human carotid plaque [16, 23]a r e
s t i l la c t i v ea n d( b )i fd i ﬀerences between symptomatic and
asymptomatic patients occur within the plaque constituents
and between plaque and blood elements.
2.MaterialsandMethods
2.1. Materials. N,O-bis(trimethylsilyl) acetamide (BSA),
cholesterol, 2-hydroxyquinoline (2HQ), diethyl p-nitro-
phenyl phosphate (paraoxon), and 4-nitrophenyl acetate
were purchased from Sigma-Aldrich. 5-(Thiobutyl)butyro-
lactone (TBBL) was synthesized in our laboratory by a pre-
viously described method [24]. 7α-Hydroxycholesterol, 7β-
hydroxycholesterol, β-epoxycholesterol, α-epoxycholesterol,
26-hydroxycholesterol, and 7-ketocholesterol were pur-
chased from Steraloids Inc. (Wilton, NH). Recombinant
PON1 from Escherichia coli was purchased from the Struc-
tural Proteomics Center, Weizmann Institute of Science
(Rehovot, Israel).
2.2. Carotid Plaques. Human carotid plaques were taken
from patients undergoing routine endarterectomy in the
Department of Vascular Surgery in Carmel Hospital (Haifa,
Israel).Bothsymptomaticandasymptomaticpatientsunder-
went surgery under local anesthesia. Patients were consid-
ered symptomatic if they had experienced stroke, transient
ischemic attack, or amaurosis fugax ipsilateral to the carotid
lesion being studied. Complete atherosclerotic plaques were
removed, including the common internal and external
carotid sections and were immediately placed in saline and
kept at −80◦C. All plaques were approved for research by
the Helsinki Committee regulations, with patient consent
(Helsinki approval number 3071). Lesion samples were laid
on ﬁlter paper to absorb the liquid and then weighed and
ground to a powder under liquid nitrogen. The powder
was extracted at 4◦C for 30min with PON activity buﬀer
(1mM CaCl2 in 50mM Tris-HCl, pH 8.0) with 0.1% (v/v)
Protease Inhibitor Cocktail and 1mM PMSF (1mL for
400mg tissue), and centrifuged at 10,000g for 10min at 4◦C.
The supernatant was removed and used for determination
o fp r o t e i nl e v e l sb yD Cp r o t e i na s s a y( B i o - R a d )a n df o r
PON activities. Precipitate was ground again under liquid
nitrogen and extracted with ethyl acetate. Ethyl acetate was
evaporated, and the LLE was dissolved in DMSO to a
ﬁnal concentration of 50mg/mL and used for detection of
lipids and oxidized lipids by liquid chromatography-mass
spectrometry (LC-MS) or gas chromatography (GC-MS).
2.3. Recombinant PON1 (rePON1). rePON1 was generated
in E. coli by directed evolution as described previously [25].
PON1 storage buﬀer (50mM Tris, pH 8.0, 50mM NaCl,
1mMCaCl 2, and 0.1% v/v tergitol) was supplemented with
0.02% (w/v) sodium azide and stored at 4◦C.
2.4. Lactonase Activity. Protein (40μg) from the plaque
homogenate, 0.1μg/mL rePON1, or 1:20 diluted serum was
takenforatotalreactionvolumeof200μL.Lactonaseactivity
was measured using TBBL as the substrate [24]. Initial rates
of hydrolysis were determined spectrophotometrically at
405nm. The assay mixture included 1mM TBBL and 1mM
CaCl2 in 50mM Tris-HCl, pH 8.0. Nonenzymatic hydrolysis
of TBBL was subtracted from the total rate of hydrolysis.
One unit of lactonase activity was equal to 1μmol of TBBL
hydrolyzed/min mL.
2.5. Paraoxonase Activity. Protein (100μg) from the plaque
homogenate or 0.2μg/mL rePON1 was taken for a total reac-
tion volume of 200μL. Paraoxonase activity was measured
using paraoxon as the substrate. Initial rates of hydrolysis
were determined spectrophotometrically at 405nm. The
basal assay mixture included 2mM paraoxon and 1mMJournal of Lipids 3
CaCl2 in 50mM glycine/NaOH buﬀer, pH 10.5. Nonenzy-
matic hydrolysis of paraoxon was subtracted from the total
rate of hydrolysis. One unit of PON1 paraoxonase activity
was equal to 1nmol of paraoxon hydrolyzed/min mL [26].
2.6. Arylesterase Activity. Protein (60μg) from the plaque
homogenate or 0.1μg/mL rePON1 was taken for a total
reaction volume of 200μL. Arylesterase activity was mea-
sured using 4-nitrophenyl acetate as the substrate. Initial
r a t e so fh y d r o l y s i sw e r ed e t e r m i n e ds p e c t r o p h o t o m e t r i -
cally at 405nm. The assay mixture included 3mM 4-
nitrophenyl acetate and 1mM CaCl2 in 50mM Tris-HCl,
pH 8.0. Nonenzymatic hydrolysis of 4-nitrophenyl acetate
was subtracted from the total rate of hydrolysis. One unit
of arylesterase activity was equal to 1μmol of 4-nitrophenyl
acetate hydrolyzed/min mL.
2.7. Plaque Triglyceride Mass. Plaque triglyceride mass was
determined using the Serum Triglyceride Kit from Sigma
(Rehovot, Israel). In short, plaque lipids were extracted in
ethyl acetate and dried under a nitrogen stream. Dry samples
were dissolved in DMSO (50mg/mL), and 50μLw a sa d d e d
to 1mL of glycerol reagent and 4mL triglyceride reagent,
vortexed and incubated for 10min at 37◦C. Triglyceride
levels were determined at 540nm according to a glycerol
standard.
2.8. Oxysterol Detection by GC-MS. S a m p l e sw e r eﬁ r s t
subjected to hydrolysis to convert all sterol esters into their
free form. The dry residue of the extracted sample was
dissolved in 0.5mL KOH solution (20% KOH in a mixture
of MeOH:DDW 70:30) and mixed for 3h at 21◦C. Two
volumes of diethyl ether were added and the pH was
adjusted to 5 with 0.5mL of citric acid (20% in DDW).
The upper organic phase was removed and the liquid phase
was extracted with another portion of 2mL diethyl ether.
The organic layers were combined, treated with sodium
sulfate, and evaporated to dryness under nitrogen purge.
Dried extracts were subjected to the silylating reagent BSA
dissolved in 1,4-dioxane (dried on 4 ˚ A molecular sieves and
passed through aluminum oxide) and heated to 80◦Cf o r
60min. Oxysterol was detected as previously described [3].
Brieﬂy, standards or dried extracts were subjected to 200μL
BSA, followed by the addition of 300μL 1,4-dioxane (treated
as before) and heated to 80◦C for 60min. Samples were
detected by GC-MS in a total ion monitoring (TIM) mode,
and 2–4 of the most representative ions were selected for
reinjection in single ion monitoring (SIM) mode. The mean
quantity of each oxysterol was calculated from calibration
curves of its standard.
2.9. Analyzing FFAs and Oxidized FFAs by LC-MS/MS. FFAs
were quantiﬁed by LC-MS/HPLC (Waters 2790) connected
to an MS (Micromass Quattro UltimaMS, UK). The HPLC
column was a 3.5mm C18 ODS XTerra column (Waters).
MS analysis of the FFAs was performed in SIM mode, using
electron spray negative ions. MS/MS analysis of the oxidized
products was performed in scan and daughter modes, using
ES−. The source temperature of the MS was set at 120◦C,
with a cone gas ﬂow of 22L/h and a desolvation gas ﬂow
of 400L/h. Peak spectra were monitored between m/z 50
and 350. Collision-induced dissociation MS was performed,
with a collision energy of 20eV and 3–3.5kV capillary
voltage. Multiple-reaction monitoring was performed under
the same conditions used to quantify the oxidized products.
2.10. Statistical Analysis. Statistical analysis was performed
using the Student paired or heteroscedastic t-test when
comparing the means of two groups. Linear regression
was calculated using GraphPad Prism 4 software. Each
experiment was repeated, separately, at least three times
(n ≥ 3). Results are presented as mean ± SEM. Clinical
parameters were analyzed using GraphPad Prism 4 software
by Contingency table with chi-square test.
3. Results
3.1. Plaque PON Activity. Immunohistochemical analysis
has recently revealed the presence of PON1, PON3 [16],
and PON2 [23] in carotid lesions. However, such analyses
do not indicate whether the enzymes in the plaque still
possess hydrolytic activity. As part of our ongoing research
into the chemical composition of the human carotid plaque,
themechanismbywhichplaquecomponentsinterrelate,and
their possible dual eﬀects with blood components, we tested
whether plaque PONs are still active. Human carotid lesions
were ground to a powder under liquid nitrogen. The powder
was extracted with Tris buﬀer and then centrifuged (see
Section 2 ). The supernatant was used for determination of
PON paraoxonase, lactonase and arylesterase activities, with
orwithouttheadditionofthePON1inhibitor2HQ.Allthree
PON activities were preserved in the plaque homogenate,
and 2HQ almost completely inhibited paraoxonase and
lactonase activities (from 2.9 to 0.014 and from 0.115 to
0.008U/mg protein, resp., Figures 1(a) and 1(b)), whereas
it only slightly decreased arylesterase activity (from 3.3
to 2.5U/mg protein) (Figure 1(c)). The eﬀects of 2HQ
on PON’s hydrolytic properties were reexamined with
rePON1. 2HQ inhibited rePON1 paraoxonase, lactonase,
and arylesterase activities almost completely (from 9006 ±
161 to 1819 ± 30, 365 ± 6t o6 5 .6 ± 0.7, and 118 ± 14 to
9.9 ± 2.8U/mg rePON1 protein, resp.) (Figures 1(d)–1(f)).
These results indicated that PONs that are present in the
plaques preserve all three of their hydrolytic activities.
3.2. Symptomatic versus Asymptomatic Patients. Atheroscle-
rotic patients have been shown to have less PON1 activity
in their blood than healthy subjects [27]. Since symptomatic
patients have some features of vulnerable plaques, their
plaques are considered to be more severe than those of
asymptomatic patients [7, 28, 29]. In the present study,
clinical parameters were compared between patients with
hypertension, hyperlipidemia, or being treated with statins
or antihypertensive drugs: no signiﬁcant diﬀerences were
found between symptomatic and asymptomatic patients
in these criteria. The symptomatic group included more4 Journal of Lipids
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Figure 1: Hydrolytic activities of paraoxonases (PONs) in human carotid plaque homogenate and of recombinant PON1 (rePON1).
(a): Homogenate paraoxonase (paraoxon), (b): lactonase (TBBL), and (c): arylesterase (4-nitrophenyl acetate) activities; (d): rePON1
paraoxonase, (e): lactonase, and (f): arylesterase activities, with or without 2-hydroxyquinoline (2HQ).
diabetic subjects than the asymptomatic group (Table 1).
Diﬀerences in plaque PON activity between symptomatic
and asymptomatic patients were assessed. Surprisingly, there
was no signiﬁcant diﬀerence in plaque lactonase activity
between the two groups (Table 2). Serum PON1 activity, as
expected, was lower (15%) in the symptomatic patients than
in the asymptomatic patients, but the diﬀerence was not
signiﬁcant (P = 0.14) (Table 2). Atherogenic components
were then compared between symptomatic and asymp-
tomatic patients, including levels of triglyceride, oxysterol,
and LA-13OOH in the plaque lipid extract, and levels of
lipoproteins and hemoglobin A1c (HbA1c) in individual
patients’ blood. The levels of various lipids and oxidized
lipids in the plaque extracts were determined by MS. NoJournal of Lipids 5
Table 1: Symptomatic and asymptomatic clinical parameters.
Symptomatic Asymptomatic P value
Age (y) 68 ±1.67 2 ±2.50 . 2
Hypertension 5/6 (83%) 10/13 (77%) 0.75
Hyperlipidemia 4/6 (67%) 10/13 (77%) 0.64
Treated with statins 5/6 (83%) 11/13 (85%) 0.94
Treated with antihypertensive drugs 4/6 (67%) 9/13 (69%) 0.91
Diabetes 3/6 (50%) 1/13 (8%) 0.035
Table 2: Atherogenic and antiatherogenic elements in the plaques and blood of symptomatic and asymptomatic patients.
Symptomatic (n = 6) Asymptomatic (n = 13) P value
Plaque
PON lactonase activity (U/mg proteins) 0.16 ±0.035 (n = 8) 0.18 ±0.054 (n = 9) N.S.
Triglyceride (% of LLE) 3.4 ±1.07 2.37 ±0.37 N.S.
7-keto (% of cholesterol) 0.38 ±0.19 0.25 ±0.05 N.S.
26-OH (% of cholesterol) 1.16 ±0.27 1.29 ±0.19 N.S.
7α-OH (% of cholesterol) 0.087 ±0.015 0.085 ±0.01 N.S.
7β-OH (% of cholesterol) 0.075 ±0.01 0.08 ±0.009 N.S.
β-epoxy (% of cholesterol) 0.096 ±0.01 0.114 ±0.02 N.S.
α-epoxy (% of cholesterol) 0.055 ±0.004 0.069 ±0.008 N.S.
LA-13OOH (μg/mg plaque) 0.012 ±0.002 0.0053 ±0.0009 0.019
Serum
PON1 lactonase activity (U/mL) 38 ±3.24 5 ±2.9N . S .
HbA1c (%) 7.17 ±0.48 6.04 ±0.15 0.065
HDL (mg/dL) 37.8 ±3.35 51.7 ±3.06 0.009
LDL (mg/dL) 79 ±13.29 0 .9 ±4.4N . S .
Cholesterol (mg/dL) 158.6 ±11.2 168.08 ±6.4N . S .
Triglyceride (mg/dL) 164.8 ±27 127.2 ±15.2N . S .
LLE: lesion lipid extract. Results are presented as mean ± SEM.
signiﬁcant diﬀerences were found in the amounts of detected
oxysterols (5,6-α-a n dβ-epoxy cholesterol, 7α-OH and 7β-
OH cholesterol, 7-keto cholesterol, and 26-OH cholesterol)
or triglycerides. In contrast, symptomatic patients had
signiﬁcantly higher (135%) amounts of LA-13OOH in their
plaques than asymptomatic patients (Table 2). In addition,
while there was no signiﬁcant diﬀerence in the amounts
of total cholesterol, LDL cholesterol, or triglyceride in the
blood, symptomatic patients had signiﬁcantly less (28%)
HDL cholesterol than the asymptomatic group (Table 2).
Symptomatic patients also had more (18%) HbA1c in their
blood than asymptomatic patients, although this diﬀerence
was only marginally signiﬁcant (Table 2).
3.3. Correlations between Plaque LA-13OOH and Elements in
t h eB l o o do ft h eS a m eI n d i v i d u a l . Previous studies from our
group have shown that LA-13OOH (with the hydroperoxide
at position 13 of linoleic acid) inhibits PON1 by speciﬁc
interaction with the enzyme’s Cys284. Thus, LA-13OOH is
considered an atherogenic factor in the plaque which can
augment oxidative stress and progression of atherosclerosis
[22]. This led us to correlate LA-13OOH level in the plaque
with other atherogenic and antiatherogenic elements in the
blood of the same patient, to assess the possible correlation
between plaque status and a speciﬁc component in the
blood.ResultsshowedthatplaqueLA-13OOHlevelisindeed
inversely correlated with two antiatherogenic elements in
the blood: serum PON1 lactonase activity (R2 = 0.35, P =
0.01, Figure 2(a)) and HDL cholesterol (R2 = 0.3, P =
0.027, Figure 2(b)). In addition, a direct correlation was
found between the two atherogenic elements, LA-13OOH
and HbA1c (R2 = 0.27, P = 0.038, Figure 2(c)).
4. Discussion
Atherogenesis is accompanied by the accumulation of oxi-
dized lipids in the arterial wall. The antioxidant enzyme
PON1 lowers lipid peroxide levels [30], protects arterial
cell walls (as well as endothelial cells, smooth muscle cells,
and macrophages) and lipoproteins (LDL and HDL) from
oxidation, inhibits oxidized LDL uptake by macrophages
[9, 10], and shows anti-inﬂammatory activities [31, 32].
Thus, the presence of PON1, PON2, and PON3 in the
human plaque may have an important role in decreasing
atherosclerotic progression. Immunohistochemical analysis
of human plaque has revealed the presence of PONs in the
lesion; during lesion progression, there is a shift of PON1
and PON3 from smooth muscle cells to macrophages [16],6 Journal of Lipids
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Figure 2: Human plaque linoleic acid hydroperoxide (LA-13OOH) level versus serum HDL, serum PON1 activity and blood hemoglobin
(Hb)A1c.HumanplaqueLA-13OOHisinverselycorrelatedwith(a):serumPON1lactonaseactivityand(b):serumHDL,but(c):positively
correlated with blood HbA1c.
whereas arterial PON2 level decreases [23]. Hence, it is
important to assess whether the PONs identiﬁed immuno-
histochemically in the plaque are still active. Our current
results show that the PONs are indeed still active in the
plaque homogenate, preserving their catalytic paraoxonase,
arylesterase, and lactonase activities. Among these activities,
only PON1 can hydrolyze paraoxon, hence we concluded
that human carotid lesion has active PON1. PON1 may
thus act as a potent reducing antioxidant enzyme not
only in the serum, but also within the plaque, leading to
attenuated atherosclerotic progression. In addition, while
2HQ inhibited rePON1 arylesterase almost completely but
only slightly decreased arylesterase in the homogenate, we
canconcludethatinthelatter,otheresterasesarepresentand
PON’s contribution is only minor.
A distinction between symptomatic and asymptomatic
patients through the identiﬁcation of biomarkers could pro-
vide information on symptom occurrence. Such biomarkers
are not yet available but are needed to make appropriate
decisions on the type of intervention required [8]. Previous
studies from our group have shown that LA-13OOH is
present in the lipid extract of the human carotid plaque, and
that it speciﬁcally inhibits rePON1 activity in a dose- and
time-dependent manner. During PON1’s interaction with
lesion LA-13OOH, the enzyme displayed a peroxidase-type
of catalysis, reducing LA-13OOH to LA-OH (hydroxide) via
the PON1 amino acid Cys284 [22]. Thus, the levels of LA-
13OOH in symptomatic and asymptomatic patients were
compared and correlated with antiatherogenic compounds
in the plaque, or in the serum derived from these patients.
Symptomatic patients had signiﬁcantly higher levels of LA-
13OOH in their plaques than their asymptomatic counter-
parts. In addition, LA-13OOH levels in the plaque were
signiﬁcantly inversely correlated with serum PON1 activity
(Figure 2(a)) and with serum HDL cholesterol (Figure 2(b)).
Although PON1 is an HDL-associated enzyme, HDL parti-
cles are highly heterogeneous in their structure, intravascular
metabolism, and biological activities [33]. Furthermore,
PON1 is only present on a relatively small fraction of the
HDL particles, mostly on the HDL3 subfraction. Thus, theJournal of Lipids 7
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Figure 3: Serum PON1 activity versus serum HDL cholesterol.
Serum PON1 activity is not correlated with serum HDL cholesterol
levels.
amount of the HDL in the blood is not necessarily correlated
with serum PON1 activity. Indeed, in this study, serum
PON1 lactonase activity was not correlated with serum
HDLlevels(Figure 3).TheseresultsindicatethatLA-13OOH
might be aﬀected, independently, by both serum PON1 and
serum HDL level. As plaque LA-13OOH has been shown
to interact with and inhibit rePON1 [22], and since PON1
is present and active, in both blood and the atherosclerotic
plaque, we determined PON1 activity in serum and plaques
derived from the same individuals and compared them
in symptomatic versus asymptomatic patients. Our results
showednodiﬀerencesinplaquePONactivitybetweensymp-
tomatic and asymptomatic atherosclerotic patients (P =
0.8). Serum PON1 activity in the symptomatic patients
was lower than in the asymptomatic patients, although this
diﬀerence was not signiﬁcant (P = 0.14) (Table 2). Plaque
PON activity may be attributed to both PON1 and the
intracellularenzymePON2,whichmaynotbeaﬀectedbythe
presence of LA-13OOH. In addition, it has been previously
shown that inhibition of rePON1 by LA-13OOH can be
prevented if certain thiols, such as the amino acid cysteine,
are present, and that PON1 inhibition by LA-13OOH can
be partially recovered if a thiol is added to the incubation
system. LA-13OOH probably oxidizes the PON1 Cys284 to
sulfenic acid, which can then be further oxidized to sulﬁnic
and sulfonic acid derivatives. In the presence of thiol, the
sulfenic acid derivative of Cys284 can be reduced back to
thiol; however, if the oxidation proceeds further, addition of
an external thiol can no longer reverse the reaction [22]. We
can, therefore, hypothesize that the presence of free cysteine
in the blood and in the plaque may also prevent LA-13OOH-
induced PON1 inactivation.
In accordance with Carr et al. [29], we did not observe
signiﬁcant diﬀerences in serum cholesterol or triglyceride
levels between symptomatic and asymptomatic patients, or
in triglyceride or oxysterol levels in the plaques themselves
(Table 2).
In addition to their higher levels of plaque LA-13OOH
and lower levels of serum HDL relative to asymptomatic
patients, there are more diabetics among the symptomatic
patients (Table 1), as characterized by a higher concentration
of blood HbA1c (Table 2). HbA1c is a glycated hemoglobin,
which is highly prone to oxidation and its level is linked
to oxidative stress. Diabetic patients are a heterogeneous
population that may diﬀer in their exposure to risk factors.
For example, haptoglobin (Hp) genotype is an independent
risk factor for vascular complications in diabetes [34]. This
study suggests LA-13OOH as a possible risk factor for
diabetic atherosclerosis development and complications, as
analyses of plaque LA-13OOH and blood HbA1c revealed a
direct correlation between these two atherogenic elements.
Levels of HbA1c are strongly correlated with mean blood
glucose [35], and high glucose concentration is known to
increase oxidative stress [36]. HbA1c is also correlated with
lipidperoxidationvalues,asshownintype1diabeticpatients
[37], as well as with plasma aldehydes (malondialdehydes)
in type 2 diabetics [38, 39]. Furthermore, Hussein et al.
[40] recently showed that the lag time required for the
initiation of LDL oxidation (in the presence of copper ions)
is inversely correlated with HbA1c concentration (mainly
whenHbA1c<7.3%).Moreover,incubationofredbloodcell
hemolysate with increasing concentrations of glucose and
with LDL or oxidized LDL results in an increased concen-
tration of HbA1c. Thus, the increased tendency for LDL to
undergo lipid peroxidation in diabetic patients contributes
to increased levels of blood HbA1c. This further emphasizes
the strong association between HbA1c and oxidative stress,
which is in agreement with the present ﬁndings pointing
to a direct link between the atherogenic compounds in the
atherosclerotic lesions and serum, such as LA-13OOH and
blood HbA1c. In addition, it is in line with the inverse
relationships shown for serum HDL and PON1 activity,
which are both antiatherogenic elements of the blood.
In conclusion, LA-13OOH levels in plaques from symp-
tomatic patients are higher than those in asymptomatic
patients’ plaques. The high levels of plaque LA-13OOH are
correlated with low levels of serum HDL, low levels of serum
PON1 lactonase activity, and increased concentrations of
blood HbA1c, all of which further accelerate atherosclerotic
progression. Thus, the levels of PON1 activities, HDL
concentration, and HbA1c content could serve as suitable
biomarkers to assess LA-13OOH level in human carotid
plaques.
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